C4 Therapeutics, Inc. (CCCC) SEC Filings & Earnings Calls

No efficacy or safety data disclosed; biomarker data only, limited read on pipeline progress.

“Biomarker data presentation; no ORR or other efficacy endpoints reported.”

Clinical-stage biopharmaceutical company with no approved products

“We are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts.” · word for word

Clinical-stage biotech with no approved products; relies on pipeline success and partnerships.

“Net loss $38.3M; revenue dependent on collaborations.”

Cash burn may require additional financing before reaching profitability.

“ATM proceeds $33.5M; no cash position disclosed in excerpt.”

Clinical trial risk; Phase 1 data may not support advancement to later stages.

“fully enrolled Phase 1 trial of cemsidomide... for the treatment of relapsed/refractory multiple myeloma” · word for word

Discontinuation of CFT8919 outside Greater China may indicate pipeline prioritization challenges.

“Decision to not advance CFT8919 into next phase outside Greater China based on evolving treatment landscape and capital priorities.”

Revenue decline due to conclusion of Merck collaboration; reliance on partnership revenue.

“Revenue decreased to $6.2M from $7.2M due to conclusion of research collaboration with Merck.”

Pre-revenue clinical-stage company with no approved products

“To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization.” · word for word

Dependence on collaboration partners for milestone revenue

“The Company is eligible to receive approximately $740 million in the aggregate in discovery, regulatory, and commercial milestone payments across the collaboration, plus tiered royalties on net sales.” · word for word

Significant accumulated deficit and ongoing losses

“The Company has incurred recurring losses since its inception, including net losses of $25.1 million and $26.3 million for the three months ended March 31, 2026 and 2025, respectively. In addition, as of March 31, 2026, the Company had an accumulated deficit of $763.8 million.” · word for word

Order Cancellation Risk

“We have received a limited number of orders for our vehicles, some of which may be cancelled by customers despite their deposit payment and online confirmation.”

Limited Model Dependence

“Our business will initially depend substantially on the sales and distribution of Eletre, Emira, Evija and Emeya.”

Manufacturing and Launch Delays

“Any delays in the manufacturing and launch of the commercial production vehicles in our pipeline could have a material adverse effect on our business.”

Homologation and Safety Standards

“Our vehicles are subject to homologations and motor vehicle safety standards and the failure to acquire homologations or satisfy mandated safety standards in jurisdictions we operate would materially and adversely affect our business and results of operations.”

Going Concern Uncertainty

“The accompanying consolidated financial statements do not include any adjustments that might result if we are unable to continue as a going concern”

Clinical-stage biotech with no approved products; reliance on pipeline success and funding.

“Company is clinical-stage; net loss of $105M in FY2025; cash runway to end of 2028 but no revenue from product sales.”

Dependence on collaboration partners for milestones and development.

“Revenue from collaborations with Merck KGaA and Biogen; milestone payments tied to partner progress.”

Significant Net Losses and Need for Additional Funding

“Our net loss was $105.0 million and $105.3 million for the years ended December 31, 2025 and 2024, respectively.” · word for word

Clinical Development Risk

“We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials.” · word for word

Dependence on Collaborations

“We have ongoing collaborations with Roche, Betta Pharma, and Merck KGaA. We may also seek to enter into additional collaborations in the future with third parties for the discovery, development and/or commercialization of certain of our product candidates. However, we may never realize the full potential benefits under these existing or potential collaborati” · word for word

Competition

“We face substantial competition, which may result in others discovering, developing or commercializing products for the same indication and/or patient population before or more successfully than we do.” · word for word

Going concern risk due to recurring losses and no product revenue

“The Company has incurred recurring losses since its inception, including net losses of $84.5 million and $70.7 million for the nine months ended September 30, 2025 and 2024, respectively.” · word for word

Dependence on collaboration agreements for revenue

“To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization.” · word for word

Potential dilution from equity offerings

“Subsequent event: underwritten offering in October 2025.”

Merck collaboration termination reduces near-term partnership revenue and validation.

“Notified by Merck of their decision to conclude the research collaboration, which will end in late November 2025.” · word for word

Clinical-stage company with no approved products; reliance on cemsidomide success and additional financing.

“Clinical-stage biopharmaceutical company; potential to earn up to an additional $225 million in proceeds if warrants exercised.”